Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.45 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414215 | 0.85 | HSD17B1 (0.60) | HSD17B1HSD17B2HDAC6MAPTMAP3K8 | |
| SCHEMBL1647714 | 0.80 | HSD17B1 (0.56) | HSD17B1HSD17B2HDAC6MAPTMAP3K8 | |
| SCHEMBL23091177 | 0.77 | HSD17B1 (0.53) | HSD17B1HSD17B2HDAC6HDAC1MAPT | |
| SCHEMBL30501674 | 0.77 | HSD17B1 (0.53) | HSD17B1HSD17B2HDAC6HDAC1MAPT | |
| SCHEMBL30910 | 0.75 | HSD17B1 (0.67) | HSD17B1HSD17B2 | |
| SCHEMBL18186525 | 0.75 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL20764039 | 0.74 | ESRRG (0.67) | HSD17B1HSD17B2MAPT | |
| SCHEMBL2947309 | 0.73 | F2 (0.53) | HDAC6MAPT | |
| SCHEMBL15571292 | 0.72 | MAPT (0.58) | HSD17B1HSD17B2HDAC6MAPT | |
| SCHEMBL3088708 | 0.72 | HDAC6 (0.71) | HDAC6HDAC1HDAC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987024-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-10-19 | — | — | EP | disclosed |
| US-7799825-B2 | Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-21 | — | — | US | disclosed |
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-03-19 | — | — | US | disclosed |
| EP-1987024-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | Istituto di Ricerche di Biologia Molecolare P. Angeletti (IT) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093827-A1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076101-A1 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors | HDAC1, HDAC4, HDAC7 | HSD17B1 54/4885HSD17B2 186/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.